Compare CLNE & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | AQST |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.4M | 521.0M |
| IPO Year | 2006 | 2007 |
| Metric | CLNE | AQST |
|---|---|---|
| Price | $2.14 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $3.49 | ★ $9.00 |
| AVG Volume (30 Days) | 996.8K | ★ 1.9M |
| Earning Date | 05-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $341,599,000.00 | $67,430,000.00 |
| Revenue This Year | $5.99 | $14.23 |
| Revenue Next Year | $17.00 | $58.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $1.30 | $2.20 |
| 52 Week High | $3.11 | $7.55 |
| Indicator | CLNE | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 50.07 |
| Support Level | $2.11 | $3.69 |
| Resistance Level | $2.26 | $4.46 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 25.32 | 39.84 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.